Welcome to our dedicated page for Biodexa Pharmaceuticals plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biodexa Pharmaceuticals plc (NASDAQ: BDRX) SEC filings page on Stock Titan provides direct access to the company’s US regulatory disclosures as a foreign private issuer. Biodexa reports to the Securities and Exchange Commission primarily through Form 20-F for its annual report and Form 6-K for current reports on material developments. These filings document clinical, regulatory and financing milestones for its lead programs eRapa, tolimidone and MTX110.
Recent Form 6-K filings describe key events such as the approval of a Clinical Trial Application (CTA) by the European Medicines Agency for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis (FAP), enrollment of the first patients into that trial, and related press releases. Other 6-Ks outline corporate actions including ADR ratio changes, results of the company’s annual general meeting, and details of capital-raising transactions like equity line of credit arrangements and a best-efforts public offering of ADS Units and pre-funded units with accompanying Series L warrants.
Through these filings, investors can review information on offering structures, warrant terms, use of proceeds, grant funding supporting the eRapa FAP program, and updates on cash and cash equivalents at specified dates. The exhibits attached to 6-Ks often include full text of securities purchase agreements, placement agency agreements and warrant forms, providing additional detail on financing terms.
Stock Titan enhances access to BDRX filings with real-time updates from EDGAR and AI-powered summaries that explain the key points of lengthy documents such as current reports and registration-related materials. Users can quickly understand how new financings, clinical trial milestones or regulatory approvals described in Form 6-K may relate to Biodexa’s broader development strategy, while still having the option to read the full SEC documents for complete context.
Biodexa Pharmaceuticals Plc reports a Schedule 13G showing Armistice Capital, LLC and Steven Boyd beneficially own 283,502 ADS, representing 9.99% of the class as of 12/31/2025. The filing states the shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital is investment manager and Steven Boyd is managing member. The Reporting Persons report shared voting and dispositive power of 283,502 ADS and no sole voting or dispositive power. The Master Fund is identified as the direct holder and noted as having the right to receive dividends or sale proceeds.
Biodexa Pharmaceuticals PLC is registering for resale up to 109,800,000 ordinary shares represented by 1,098 American Depositary Shares held by selling shareholders, and is updating investors via a prospectus supplement and attached Form 6-K.
The company also reports an exclusive license and collaboration agreement with Otsuka Pharmaceutical, granting Biodexa rights outside Japan to develop, manufacture and commercialize MTX240, a Phase 1-ready molecular glue therapeutic candidate initially aimed at treating gastrointestinal stromal tumors. Biodexa will handle development, manufacturing and commercialization in its licensed territory, with Otsuka eligible for an upfront payment, development and regulatory milestones, tiered mid-single-digit royalties on net sales, and a share of certain sublicense income.
Biodexa Pharmaceuticals PLC filed a prospectus supplement covering the resale by existing shareholders of up to 171,700,000 ordinary shares, represented by 1,717 American Depositary Shares. The supplement incorporates a new report describing a strategic licensing transaction.
The company entered an exclusive collaboration with Otsuka Pharmaceutical, obtaining worldwide rights outside Japan to develop, manufacture and commercialize MTX240 (OPB-171775), a Phase 1-ready molecular glue for gastrointestinal stromal tumors. Otsuka receives an upfront payment, potential development and regulatory milestones, and tiered mid-single-digit royalties on net sales, with MTX240 protected by composition of matter patents extending through 2037.
Biodexa Pharmaceuticals PLC files a prospectus supplement covering the resale of up to 4,349,000,000 ordinary shares represented by 43,490 American Depositary Shares by existing shareholders. The supplement also incorporates a Form 6-K describing a new license and collaboration agreement.
Biodexa obtained an exclusive license from Otsuka Pharmaceutical to develop, manufacture and commercialize MTX240 (OPB-171775) for all human therapeutic uses outside Japan. MTX240 is a Phase 1-ready molecular glue candidate initially aimed at gastrointestinal stromal tumors, with an upfront payment, development and regulatory milestones, and tiered mid-single digit royalties on net sales, supported by patents extending through 2037.
Biodexa Pharmaceuticals PLC filed a prospectus supplement covering the resale of up to 2,846,100,000 ordinary shares represented by 24,861 American Depositary Shares. The supplement incorporates a Form 6-K describing an exclusive license and collaboration with Otsuka for MTX240, a Phase 1-ready molecular glue for gastrointestinal stromal tumours.
Biodexa receives exclusive rights to develop, manufacture and commercialize MTX240 outside Japan, while Otsuka retains Japanese rights. Otsuka receives an upfront payment, potential one-time development and regulatory milestones, tiered mid-single-digit royalties on net sales, and a share of sublicense income. MTX240’s patents extend through 2037 and preclinical data suggest activity in tyrosine kinase inhibitor-resistant GIST models, aligning with Biodexa’s rare disease oncology strategy.
Biodexa Pharmaceuticals files a prospectus supplement to its existing Form F-1 to incorporate a new Form 6-K describing an exclusive license and collaboration with Otsuka Pharmaceutical for MTX240, a Phase 1-ready molecular glue therapeutic candidate initially aimed at treating gastrointestinal stromal tumors (GIST).
Under the agreement, Biodexa receives exclusive rights to develop, manufacture and commercialize MTX240 worldwide excluding Japan, while Otsuka retains Japanese rights. Biodexa made an upfront payment and Otsuka is entitled to one-time development and regulatory milestones, tiered mid-single-digit royalties on net sales, and a share of any sublicense income.
The attached press release explains that MTX240 (OPB-171775) uses a molecular glue mechanism to induce apoptosis in GIST cells through a pathway independent of KIT signaling and has shown dose-dependent anti-tumor activity in tyrosine kinase inhibitor–resistant patient-derived xenograft models, targeting a population with significant unmet medical need.
Biodexa Pharmaceuticals PLC filed a prospectus supplement for the resale by a selling shareholder of up to 341,352,000,000 ordinary shares, represented by 3,413,520 American Depositary Shares. The supplement also incorporates a Form 6-K describing a new licensing deal.
The company entered into an exclusive, worldwide (excluding Japan) license and collaboration agreement with Otsuka Pharmaceutical for OPB-171775, a Phase 1-ready molecular glue therapeutic to be developed as MTX240 for gastrointestinal stromal tumors. Biodexa will handle development, manufacturing, and commercialization outside Japan, while Otsuka keeps Japanese rights.
Otsuka received an upfront payment and may receive one-time development and regulatory milestones, plus tiered mid-single-digit royalties on net sales and a share of any sublicense income. MTX240 is backed by composition-of-matter patents in major territories extending through 2037.
Biodexa Pharmaceuticals has entered an exclusive license and collaboration agreement with Otsuka Pharmaceutical, gaining worldwide rights outside Japan to develop, manufacture and commercialize OPB-171775, now called MTX240, a Phase 1-ready molecular glue drug candidate for gastrointestinal stromal tumors (GIST).
MTX240 uses a novel mechanism by bringing PDE3a and SLFN12 proteins together in GIST cells to trigger apoptosis through a pathway independent of KIT signaling, aiming to overcome resistance to existing tyrosine kinase inhibitors. In resistant patient-derived xenograft mouse models, MTX240 showed dose-dependent anti-tumor activity.
Biodexa will handle development and commercialization in its territory and has paid an upfront fee, with Otsuka eligible for development and regulatory milestones and mid-single digit tiered royalties. MTX240 is covered by composition of matter patents in major regions through 2037.
Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC and Hal Mintz report a 9.9% beneficial ownership stake in Biodexa Pharmaceuticals Plc ADSs. The filing states they collectively beneficially own 217,600 ADSs, with shared power to vote and dispose of all of these securities and no sole voting or dispositive power. Each reporting person lists the same 217,600 ADSs and 9.9% of the class as their beneficial ownership.
The group certifies that the ADSs were not acquired and are not held for the purpose of changing or influencing control of Biodexa Pharmaceuticals Plc, and that they are not participating in any transaction with that purpose or effect, other than potential activities tied to a nomination under the specified proxy rule.
Biodexa Pharmaceuticals PLC has appointed Fiona Sharp as Chief Financial Officer, Corporate Secretary and member of the Board of Directors, effective January 5, 2026. She will serve as a director until the company’s annual general meeting in 2026, while Stephen Stamp continues as Chief Executive Officer after relinquishing the CFO and Corporate Secretary roles.
Sharp, aged 57, has been the company’s Group Financial Controller since December 2019 and previously held senior finance roles at Hywell DDA University Health Board and Chime Communications Limited. The company states that she has no family relationships with existing directors or executives, no selection arrangements with other parties, and no reportable transactions with the company. The appointment information is incorporated by reference into Biodexa’s existing Form S-8 and Form F-3 registration statements.